New hope for rare gut cancer: targeted drug enters trial for patients out of options
NCT ID NCT07347314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests enfortumab vedotin, a targeted drug that homes in on a protein called Nectin-4 found on many small bowel cancer cells. The study enrolls 27 adults whose cancer has worsened despite platinum-based chemotherapy or who cannot tolerate it. Participants receive the drug intravenously three weeks out of four. Researchers will measure how many patients' tumors shrink and track safety, hoping to find a new standard treatment for this rare and aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Enfortumab vedotin (an antibody-drug conjugate that targets Nectin-4 on cancer cells and delivers a chemotherapy payload)
- What this could lead to
- If it works, this could provide a new treatment option for people with advanced small bowel adenocarcinoma who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 27 participants and no comparison group. The drug may not shrink tumors or may cause significant side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SMALL BOWEL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Japan
-
National Cancer Center Hospital
RECRUITINGTokyo, Japan
-
Osaka International Cancer Institute
RECRUITINGOsaka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.